Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access